594810-90-9

Basic information

• Product Name: 2-Bromo-4-fluorophenacyl bromide
• Synonyms: 2-Bromo-4-fluorophenacyl bromide;2,2'-Dibromo-4-fluoroacetophenone, 2-Bromo-1-(2-bromo-4-fluorophenyl)ethan-1-one
• CAS NO: 594810-90-9
• Molecular Formula: C8H5Br2FO
• Molecular Weight: 296
• Mol File: 594810-90-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Bromo-4-fluorophenacyl bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-4-fluorophenacyl bromide(594810-90-9)
• EPA Substance Registry System: 2-Bromo-4-fluorophenacyl bromide(594810-90-9)

Safety Data

• Hazardous Substances Data: 594810-90-9(Hazardous Substances Data)

Usage

General Description

2-Bromo-4-fluorophenacyl bromide, also known as BFB, is a chemical compound used in the synthesis of pharmaceuticals and in organic chemistry research. It is a versatile reagent that is commonly used for the synthesis of amides, esters, and other biologically active compounds. BFB is a potent halogenating agent, and its high reactivity makes it useful in a wide range of chemical reactions. It is also used as a coupling reagent in peptide synthesis and as a precursor for the preparation of fluorescent probes and labels. Despite its high reactivity, BFB has been found to be relatively stable under typical storage conditions, making it a valuable tool in organic synthesis and pharmaceutical development.

Upstream product

• 1006-39-9 1-(2-bromo-4-fluorophenyl)ethanone 

Relevant articles and documents

Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors

Autotaxin (ATX) is a secreted enzyme playing a major role in the production of lysophosphatidic acid (LPA) in blood through hydrolysis of lysophosphatidyl choline (LPC). The ATX-LPA signaling axis arouses a high interest in the drug discovery industry as it has been implicated in several diseases including cancer, fibrotic diseases, and inflammation, among others. An imidazo[1,2-a]pyridine series of ATX inhibitors was identified out of a high-throughput screening (HTS). A cocrystal structure with one of these compounds and ATX revealed a novel binding mode with occupancy of the hydrophobic pocket and channel of ATX but no interaction with zinc ions of the catalytic site. Exploration of the structure-activity relationship led to compounds displaying high activity in biochemical and plasma assays, exemplified by compound 40. Compound 40 was also able to decrease the plasma LPA levels upon oral administration to rats.

COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseasesby administering the compound of the invention.

BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS

The invention relates to novel heterocycles of formula (I), processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.